News

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees…

2 years ago

Venus Concept Inc. Announces Issuance of $2.0M of Convertible Notes

Sale of convertible notes provides additional financial flexibility and support for the Company’s path to cash flow breakevenTORONTO, Jan. 19,…

2 years ago

Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence

Strategic licensing plan prepares Company for future regulatory approvalsVANCOUVER, British Columbia, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp.…

2 years ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates…

2 years ago

Coloplast A/S – Q1 2023/24 Earnings Release – Invitation for conference call on 9 February 2024 at 11.00am CET

Friday, 9 February 2024 at 11.00 - 12.00 CETIn connection with the publication of Coloplast’s interim financial results for Q1 2023/24, to be released…

2 years ago

Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

Allschwil, Switzerland, January 19, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs…

2 years ago

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

REVASCOR Increases Size of Left Heart Chamber and Improves Surgical Outcomes in Children with Hypoplastic Left Heart Syndrome: Results Published…

2 years ago

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and…

2 years ago

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap®…

2 years ago

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming…

2 years ago